China's medical products administrator approved Abbisko Cayman's (HKG:2256) registrational clinical study for the ABSK011 drug, according to a Monday filing with the Hong Kong Exchange.
Irpagratinib, as the drug is also known, is indicated for advanced or unresectable liver cancer, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.